Healthcare Providers and Services
Company Overview of Genoptix, Inc.
Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial services, custom assay development, and companion diagnostics development services. The company’s services include chromogenic and fluorescent immunohistochemistry and phospho-immunohistochemistry as single-color or multiplexed assays; cytogenetics and flow cytometry; and a range of molecular testing platforms. The company also performs specialty assays on oncology specimens to support patient diagnosis and stratification for trial to determine pharmacodynamic status, or to assess disease prognosis and monitor its progression; and designs and optimizes custom assays specific to...
1811 Aston Avenue
Carlsbad, CA 92008
Founded in 1999
Key Executives for Genoptix, Inc.
President of Cartesian Medical Group and Chief Medical Officer of Cartesian Medical Group
Chief Technical Officer and Senior Vice President of Business Development & Medical Affairs
Chief Information Officer and Senior Vice President
Compensation as of Fiscal Year 2017.
Genoptix, Inc. Key Developments
Genoptix, Inc. and Bionano Genomics, Inc. Announce Strategic Alliance
Jun 28 17
Genoptix, Inc. and Bionano Genomics®, Inc. announced an exclusive agreement to co-develop information-rich diagnostics for selected hematologic oncology indications in the US using Bionano’s Saphyr™ System. Bionano’s Saphyr System accurately visualizes the structure of a genome from a simple DNA sample isolated directly from cancer cells, removing the need for cell culture. It allows for the detection of all major types of structural variants with a sensitivity far greater than sequencing based methods, and with much higher resolution than karyotyping or fluorescence in situ hybridization (FISH) can provide. The development efforts of Genoptix and Bionano will focus on indications within hematology-oncology where detection of large structural variations of the genome is required for accurate diagnosis. Cancer cells typically show a large number of major rearrangements of the genome, and their presence or absence can affect the characteristics of the tumor and its response to treatment and, therefore, direct clinical care.
Genoptix, Inc. Announces Management Appointments
Mar 7 17
Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. Joseph M. Limber, who previously served as CEO of Prometheus Laboratories, will lead the new Genoptix as Chief Executive Officer. He will be joined by Mark Spring as Chief Financial Officer and Juan Estruch as Head of Corporate Development, both of whom served with Limber on the executive team at Prometheus Laboratories.
Genoptix, Inc. Announces Executive Appointments
Jan 30 17
In partnership with Ampersand Capital Partners and 1315 Capital, has entered into a definitive agreement to acquire the commercial laboratory of Genoptix, Inc. This transaction is expected to close in the first quarter of 2017 subject to certain closing conditions. Joseph M. Limber, who previously served as CEO of Prometheus Laboratories, will become CEO of Genoptix upon completion of the transaction. Mark Spring, who served as CFO of Prometheus, will serve as CFO of Genoptix. Under Mr. Limber's leadership, Prometheus became a leading commercial U.S. specialty diagnostic and therapeutic company in gastroenterology and oncology, with an innovative oncology diagnostic platform, culminating in its successful sale to Nestle Health Sciences in 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 30, 2017